Teva Pharma said that the positive opinion was based on the significant results from the clinical trials evaluating, NOMAC-E2.
NOMAC-E2 is a monophasic regimen containing an estrogen which is structurally identical to the major estrogen produced by the ovaries of healthy non pregnant women, combined with a selective progesterone analogue (nomegestrol acetate).
If approved for marketing by the European Commission, NOMAC-E2 will be marketed by Teva/Theramex in select European markets.